Illumina EPS beats by $0.22, beats on revenue

• Illumina (NASDAQ:ILMN): Q3 Non-GAAP EPS of $1.02 beats by $0.22; GAAP EPS of $1.21 beats by $0.56.
• Revenue of $794M (-12.5% Y/Y) beats by $80.03M.
• Cash flow from operations of $153M compared to $267M last year.
• “Our business accelerated in the third quarter with sequencing consumable revenue growing 29% from the second quarter. We’re also making progress incorporating genomics into the standard of care in non-invasive pre-natal testing, oncology therapy selection, and genetic disease diagnosis. Looking forward, we believe our planned acquisition of GRAIL will catalyze a new era of early cancer detection, transforming cancer survivability and opening up the largest clinical application of genomics we’ve seen.” said Francis deSouza, CEO.
•  Release
• https://seekingalpha.com/news/3628567-illumina-eps-beats-0_22-beats-on-revenue